Evidence map›Paper›PMID 41243030›Full record

ReviewJournal of neurology2025

The overlooked side of myasthenia gravis: the non-motor manifestations-a comprehensive review.

Christian Messina

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Christian MessinaAzienda Sanitaria Provinciale Catania, Catania, Italy. chry.messina@gmail.com.ORCID http://orcid.org/0000-0003-3027-7863

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating muscle weakness due to antibody-mediated impairment of acetylcholine receptor (AChR) function. Traditionally, MG has been regarded as a disease primarily affecting skeletal muscles, and most research has focused on its motor manifestations. However, increasing evidence suggests that MG is a systemic disorder that can also present with a wide range of non-motor symptoms, which may significantly affect both quality of life and disease outcomes. This review provides a comprehensive overview of the non-motor manifestations of MG, including autonomic, cognitive, psychiatric, sensory, and gastrointestinal disturbances, as well as cardiovascular and sleep abnormalities. We discuss the underlying pathophysiological mechanisms that may explain these symptoms, focusing on immune dysregulation, autonomic imbalance, and potential antibody cross-reactivity with nicotinic acetylcholine receptor subtypes in non-skeletal tissues. Moreover, diagnostic and therapeutic implications are addressed, emphasizing the need for multidisciplinary management to adequately assess and treat these often-overlooked aspects of the disease. Although current evidence remains limited, mainly derived from small cohorts or case reports, the recognition of non-motor symptoms in MG represents an essential step toward a more holistic understanding of the disease. Future research should aim to elucidate their prevalence, underlying mechanisms, and treatment strategies through well-designed, prospective studies. Overall, this review highlights the importance of incorporating the assessment of non-motor manifestations into routine MG care to improve patient outcomes and quality of life.

Indexed as

Autonomic Nervous System DiseasesMyasthenia GravisHumansAssessmentAutonomic dysfunctionMyasthenia gravisNon-motor symptomsQuality of life

Identifiers

PMID41243030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.